Why is it hard for Māori and Pasifika to access weight loss drugs in NZ?

Despite facing higher rates of obesity, Māori and Pasifika individuals in New Zealand have significantly limited access to GLP-1 weight loss drugs such as Wegovy. Data reveals that these groups constitute a small minority of those who have managed to access these medications.

The reasons behind this disparity are multifaceted and are still being explored. Factors such as cost, cultural appropriateness of treatment, and healthcare provider bias may contribute to the low uptake among these communities. Further research is needed to understand the specific barriers and to develop strategies that ensure equitable access to effective weight management solutions for all New Zealanders.

Obesity is a significant health concern, particularly within Māori and Pasifika populations, who experience disproportionately higher rates compared to other ethnic groups. Access to advanced treatments like GLP-1 agonists could offer a crucial pathway to improved health outcomes, making the current inequities in access a pressing public health issue.